Skip to content

EBIT at other companies

Vera Therapeutics logo
Vera TherapeuticsVERA
-$125.13M-119%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
-$41.37M+12.7%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$53.7M+2.4%
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO
-$43.45M-85.8%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K
Free cash flow-$15.6M-183%

Valuation

See full
Market cap$724.95M+787%
Enterprise value$717.07M+1,247%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0.0×
Current ratio27.9×+13.6×

Where this comes from

Calculated from Climb Bio, Inc.’s reported figures.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Climb Bio, Inc.'s EBIT?
Climb Bio, Inc. (CLYM) reported EBIT of -$15.21M in Q1 2026.
How has Climb Bio, Inc.'s EBIT changed year-over-year?
Climb Bio, Inc.'s EBIT increased by 33.9% year-over-year, from -$23.02M to -$15.21M.
What is the long-term trend for Climb Bio, Inc.'s EBIT?
Over 4 years (2021 to 2025), Climb Bio, Inc.'s EBIT has grown at a 17.5% compound annual growth rate (CAGR), from -$35.67M to -$67.88M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.